WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Phillip Huang Weijie: WuXi Biologics (02269) Kursziel von 142 Yuan, Stop-Loss-Preis von 116 Yuan https://www.quamnet.com/post/P-SxF1X8l9yXGSKm9BBI_ The Hang Seng Index fell more than 500 points at intraday, and the drop continued to expand by more than 2%. WuXi Biologics (02269) fell more than 7% and led the blue chip to drag the index nearly 70 points https://m.jrj.com.cn/madapter/hk/2021/10/04095833588615.shtml

HSI Deepens Slide to Over 600 pts; Financials, New Econ, Pharmas Decline; Alibaba Tests Trough  http://www.aastocks.com/en/stocks/news/aafn-con/RUM.211004_100821/recommend-news HSI opened low by 96 pts or 0.4% to post at 24,478 this morning, as it was weighed down by MEITUAN-W (03690 HK) ,  the property and financial sectors. The index then further widened its drop to 662 pts or 2.7%; last posted 23,913, on a turnover of $26.8 billion. The blue chip stocks broadly stumbled, with the pharmaceutical sectors facing the largest pressure. ...

Sihuan Pharmaceutical and WuXi Biologics develop new tumor treatment drugs https://m.hkej.com/landing/mobarticle2/id/2925935/%E5%9B%9B%E7%92%B0%E9%86%AB%E8%97%A5%E5%A4%A5%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9%E7%A0%94%E7%99%BC%E8%85%AB%E7%98%A4%E6%B2%BB%E7%99%82%E6%96%B0%E8%97%A5 Sihuan Pharmaceutical ( 00460 ) announced that it has reached a R&D and production service cooperation with WuXi Biologics ( 02269 ) for an innovative tumor treatment drug KM501 bi-antibody ADC. It is currently in the pre-development stage of a new drug clinical trial application (IND). ...

Freitag bleibt HK wieder geschlossen. Noch in Bezug auf den Markt ab morgen: Die Auswirkungen der Aussetzung von Southbound Trading https://skypost.ulifestyle.com.hk/column/article/3069011/%E6%B8%AF%E8%82%A1%E9%80%9A%E6%9A%AB%E5%81%9C%E7%9A%84%E5%BD%B1%E9%9F%BF

Morgen ist die Börse in HK geschlossen.

Der Interim Report steht zum Download bereit: 2021 Interim Report Download https://www.wuxibiologics.com/wp-content/uploads/2021-Interim-Report.pdf

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs https://finance.yahoo.com/news/biovaxys-bioproduction-partner-wuxi-biologics-070000538.html

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210913_110957/hk-stock-news HSI Craters Over 500 Pts on New Econ Shrs; Meituan/ WuXi Bio/ Galaxy/ Sands/ Wharf REIC Dive Over 5%

WuXi Biologics: Leading Global Biologics Outsourcing Company https://seekingalpha.com/article/4454473-wuxi-biologics-leading-global-biologics-outsourcing-company Summary • WuXi Biologics is the largest biologics outsourcing company in China, and among the top three industry players in the world. • The key risks for the stock are geopolitical tensions, policy risks in China, and weaker-than-expected profitability going forward. • WuXi Biologics trades at 140.5 times consensus forward FY 2021 P/E and and 97.1 times consensus forward FY 2022 P/E. ...

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date https://www.prnewswire.com/news-releases/wuxi-biologics-received-first-manufacturing-license-from-japan-and-completed-12-global-regulatory-inspections-in-2021-year-to-date-301366900.html • Successfully completed 12 regulatory inspections so far this year ...

Eher noch mal allgemein zu den earnings und ohne Bezug zu der großen Tranche, die heute morgen in HK den Besitzer gewechselt hat: Karen Kwok: Hong Kong stocks are expected to repeat WuXi Biologics (02269 HK) outlook in the short term http://www.aastocks.com/tc/stocks/news/aafn-con/.hk.210901_100022/latest-news

UBS: To WuXi Biologics (02269) "Buy" rating target price of 142 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/08/30153233352206.shtml WuXi Biologics (02269 HK) produces 100 million doses of vaccine stock solution https://www.finet.hk/newscenter/news_content/612c2422bde0b305f9686767

Morgan Stanley: To WuXi Biologics (02269) "overweight" rating target price rose 3.6% to 170 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/08/26143233323765.shtml

Ziemlich ausführlich begründet und ist ein Fall für den Übersetzer: Zhongtai Securities: Maintain WuXi Biologics (02269) "Buy" rating, expecting new technology platforms to gradually contribute to new growth https://m.jrj.com.cn/madapter/hk/2021/08/25150633316397.shtml

https://finance.sina.cn/hkstock/gsxw/2021-08-24/detail-ikqcfncc4770750.d.html?from=wap WuXi Biologics (02269) announced that on August 24, 2021, the board of directors has approved the grant of a total of 4,869,500 restricted shares to the company's 745 employees, subject to acceptance by the grantee. The new shares that the company will issue and allot to the trustee are equivalent to approximately 0.11% of the company’s issued share capital on the date of this announcement and approximately 0.11% of the company’s enlarged issued share capital after the issuance and allotment.